12406 HORESHAM STREET, CARMEL, IN
News, Underwriting Agreement
Investor Presentation
Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
Earnings Release
Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
Reg. FD
Material disclosure
Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Q2
Q1
FY 2024
Q3
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration of Securities
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
S-1MEF